Linzagolix choline is under clinical development by ObsEva and currently in Phase III for Pain. According to GlobalData, Phase III drugs for Pain have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Linzagolix choline’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Linzagolix choline overview

Linzagolix (Yselty) is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist. It is formulated as film coated tablets for oral route of administration. Yselty is indicated for the management of moderate to severe symptoms of uterine fibroids (UF) in adult women (over 18 years of age) of reproductive age.

Linzagolix choline is under development for the treatment of endometriosis associated pain and uterine fibroids. It is a new chemical entity (NCE). The drug candidate is administered orally as a film coated tablet. KLH-2109 targets gonadotrophin-releasing hormone (GnRH).

ObsEva overview

ObsEva is a clinical-stage biopharmaceutical company that develops and commercializes drugs for women’s reproductive health and pregnancy. The company’s product portfolio comprises pipeline products for controlling preterm labor by reducing inflammation, decreasing uterine contractions, and preventing cervical changes and membrane ruptures; for the treatment of pain in association with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women and to decrease contractions, improve uterine blood flow and enhance the receptivity of the endometrium to embryo implantation. ObsEva is headquartered in Geneva, Switzerland.

For a complete picture of Linzagolix choline’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.